Targeted and Untargeted Proteomics Approaches in Biomarker Development

An enormous amount of research effort has been devoted to biomarker discovery and validation. With the completion of the human genome, proteomics is now playing an increasing role in this search for new and better biomarkers. Here, what leads to successful biomarker development is reviewed and how these features may be applied in the context of proteomic biomarker research is considered. The “fit‐for‐purpose” approach to biomarker development suggests that untargeted proteomic approaches may be better suited for early stages of biomarker discovery, while targeted approaches are preferred for validation and implementation. A systematic screening of published biomarker articles using MS‐based proteomics reveals that while both targeted and untargeted technologies are used in proteomic biomarker development, most researchers do not combine these approaches. i) The reasons for this discrepancy, (ii) how proteomic technologies can overcome technical challenges that seem to limit their translation into the clinic, and (iii) how MS can improve, complement, or replace existing clinically important assays in the future are discussed.

[1]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[2]  James D Brooks,et al.  Translational genomics: the challenge of developing cancer biomarkers. , 2012, Genome research.

[3]  Christoph H Borchers,et al.  MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum , 2014, Expert review of proteomics.

[4]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[5]  W. Catalona,et al.  The Prostate Health Index: a new test for the detection of prostate cancer , 2014, Therapeutic advances in urology.

[6]  E. Fung,et al.  A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. , 2010, Clinical chemistry.

[7]  Darryl B. Hardie,et al.  Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays , 2018, Communications Biology.

[8]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[9]  A. Shevchenko,et al.  Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry , 1996, Nature.

[10]  Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis , 2015, Familial Cancer.

[11]  Loïc Dayon,et al.  Analysis of 1508 Plasma Samples by Capillary-Flow Data-Independent Acquisition Profiles Proteomics of Weight Loss and Maintenance , 2019, Molecular & Cellular Proteomics.

[12]  R. Holland What makes a good biomarker? , 2016, Advances in Precision Medicine.

[13]  Richard E Higgs,et al.  Label-free LC-MS method for the identification of biomarkers. , 2008, Methods in molecular biology.

[14]  S. Badve,et al.  Predictive Biomarkers in Oncology , 2019, Springer International Publishing.

[15]  D. Liebler,et al.  Targeted Quantitation of Proteins by Mass Spectrometry , 2013, Biochemistry.

[16]  M. Mann,et al.  Mass spectrometry–based proteomics turns quantitative , 2005, Nature chemical biology.

[17]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[18]  Douglas B. Johnson,et al.  Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma* , 2017, Molecular & Cellular Proteomics.

[19]  R. Zahedi,et al.  Quantifying Missing (Phospho)Proteome Regions with the Broad-Specificity Protease Subtilisin. , 2017, Analytical chemistry.

[20]  Christoph H Borchers,et al.  Method and platform standardization in MRM-based quantitative plasma proteomics. , 2013, Journal of proteomics.

[21]  H. Cooper,et al.  Compound heterozygotes and beta‐thalassemia: Top‐down mass spectrometry for detection of hemoglobinopathies , 2014, Proteomics.

[22]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[23]  Min-Yuan Chou,et al.  Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry. , 2015, Analytical chemistry.

[24]  M. Moran,et al.  Evosep One Enables Robust Deep Proteome Coverage Using Tandem Mass Tags while Significantly Reducing Instrument Time. , 2019, Journal of proteome research.

[25]  Melvin A. Park,et al.  Trends in trapped ion mobility – Mass spectrometry instrumentation , 2019, TrAC Trends in Analytical Chemistry.

[26]  K. Mechtler,et al.  Improved Sensitivity in Low-Input Proteomics Using Micropillar Array-Based Chromatography , 2019, bioRxiv.

[27]  B. Kuster,et al.  A bead-based western for high-throughput cellular signal transduction analyses , 2016, Nature Communications.

[28]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[29]  Thomas Stoll,et al.  Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II , 2017, Diabetes Care.

[30]  M. Lowenthal,et al.  Quantification of cardiac troponin I in human plasma by immunoaffinity enrichment and targeted mass spectrometry , 2018, Analytical and Bioanalytical Chemistry.

[31]  Daniel T Holmes,et al.  Quantitation of Insulin Analogues in Serum Using Immunoaffinity Extraction, Liquid Chromatography, and Tandem Mass Spectrometry. , 2016, Methods in molecular biology.

[32]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[33]  Yafeng Zhu,et al.  In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta , 2019, eLife.

[34]  M. Vogeser,et al.  An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[35]  Haixu Tang,et al.  Interlaboratory Study on Differential Analysis of Protein Glycosylation by Mass Spectrometry: The ABRF Glycoprotein Research Multi-Institutional Study 2012* , 2013, Molecular & Cellular Proteomics.

[36]  D. Hilbert,et al.  The discovery and development of belimumab: the anti-BLyS–lupus connection , 2012, Nature Biotechnology.

[37]  R. Zahedi Joining forces: studying multiple post-translational modifications to understand dynamic disease mechanisms , 2016, Expert review of proteomics.

[38]  J. Ioannidis,et al.  Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.

[39]  Carl-Magnus Clausson,et al.  Insufficient antibody validation challenges oestrogen receptor beta research , 2017, Nature Communications.

[40]  R. Popp,et al.  How iMALDI can improve clinical diagnostics. , 2018, The Analyst.

[41]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[42]  Vicky A Legrys,et al.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.

[43]  R. Branca,et al.  Isoelectric point-based fractionation by HiRIEF coupled to LC-MS allows for in-depth quantitative analysis of the phosphoproteome , 2017, Scientific Reports.

[44]  J. Yates,et al.  Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. , 1995, Analytical chemistry.

[45]  René P Zahedi,et al.  The next level of complexity: Crosstalk of posttranslational modifications , 2014, Proteomics.

[46]  Ryan W. Benz,et al.  A large-scale and robust dynamic MRM study of colorectal cancer biomarkers. , 2018, Journal of proteomics.

[47]  Bruno Manadas,et al.  SWATH‐MS as a tool for biomarker discovery: From basic research to clinical applications , 2017, Proteomics.

[48]  K. Dhingra Oncology 2020: a drug development and approval paradigm. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  J. R. Perkins,et al.  Nanoscale separations: Capillary liquid chromatography-mass spectrometry and capillary zone electrophoresis-mass spectrometry for the determination of peptides and proteins , 1991 .

[50]  L. Sanders From Thebes to Toronto and the 21st Century: An Incredible Journey , 2002 .

[51]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[52]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[53]  Pei Wang,et al.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.

[54]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[55]  Mathias Wilhelm,et al.  Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning , 2019, Nature Methods.

[56]  Darryl B. Hardie,et al.  Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. , 2014, Biochimica et biophysica acta.

[57]  Wilhelm Schänzer,et al.  Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions , 2014, Expert review of proteomics.

[58]  Patrick M M Bossuyt,et al.  Quantifying the accuracy of a diagnostic test or marker. , 2012, Clinical chemistry.

[59]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[60]  M. Huss,et al.  HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics , 2013, Nature Methods.

[61]  Marius Ilie,et al.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients , 2016, Virchows Archiv.

[62]  L. Deterding,et al.  Nanoscale separations combined with tandem mass spectrometry. , 1991, Journal of chromatography.

[63]  Yanbao Yu,et al.  S-Trap, an Ultrafast Sample-Preparation Approach for Shotgun Proteomics. , 2018, Journal of proteome research.

[64]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[65]  Yiling Lu,et al.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.

[66]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[67]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[68]  A. Jaffe,et al.  Troponin: the biomarker of choice for the detection of cardiac injury , 2005, Canadian Medical Association Journal.

[69]  D. Chan,et al.  Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges , 2013, Clinical Proteomics.

[70]  Ronald J Moore,et al.  Enhancing bottom‐up and top‐down proteomic measurements with ion mobility separations , 2015, Proteomics.

[71]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[72]  D. Pal,et al.  Mass Spectrometry-Based Diagnosis of Hemoglobinopathies: A Potential Tool for the Screening of Genetic Disorder , 2016, Biochemical Genetics.

[73]  Tanveer S. Batth,et al.  Protein Aggregation Capture on Microparticles Enables Multipurpose Proteomics Sample Preparation* , 2019, Molecular & Cellular Proteomics.

[74]  Darryl B. Hardie,et al.  A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. , 2010, Journal of proteome research.

[75]  U. Scherf,et al.  Approval of novel biomarkers: FDA's perspective and major requests , 2010, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[76]  C. Eyers,et al.  RePLiCal: A QconCAT Protein for Retention Time Standardization in Proteomics Studies. , 2016, Journal of proteome research.

[77]  P. Sundgren,et al.  Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma , 2019, Clinical Cancer Research.

[78]  Matthias Mann,et al.  Parallel Accumulation-Serial Fragmentation (PASEF): Multiplying Sequencing Speed and Sensitivity by Synchronized Scans in a Trapped Ion Mobility Device. , 2015, Journal of proteome research.

[79]  J. Cadeddu,et al.  Spurious prostate‐specific antigen (PSA) recurrence after radical prostatectomy: Interference by human antimouse heterophile antibodies , 2007, International journal of urology : official journal of the Japanese Urological Association.

[80]  Eugene A. Kapp,et al.  Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.

[81]  Melvin A. Park,et al.  Online Parallel Accumulation–Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer* , 2018, Molecular & Cellular Proteomics.

[82]  W. Catalona,et al.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. , 2010, The Journal of urology.

[83]  Matthias Mann,et al.  Revisiting biomarker discovery by plasma proteomics , 2017, Molecular systems biology.

[84]  Knut Reinert,et al.  OpenMS – An open-source software framework for mass spectrometry , 2008, BMC Bioinformatics.

[85]  J. Olsen,et al.  Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics. , 2014, Journal of proteome research.

[86]  Steven P Gygi,et al.  Streamlined Tandem Mass Tag (SL-TMT) Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling Using Tandem Mass Tag-Synchronous Precursor Selection-MS3. , 2018, Journal of proteome research.

[87]  C. Borchers,et al.  An online 2D-reversed-phase - Reversed-phase chromatographic method for sensitive and robust plasma protein quantitation. , 2017, Journal of proteomics.

[88]  C. E. Parker,et al.  Mass-spectrometry-based clinical proteomics--a review and prospective. , 2010, The Analyst.

[89]  R. Zahedi,et al.  Proteome-wide detection of S-nitrosylation targets and motifs using bioorthogonal cleavable-linker-based enrichment and switch technique , 2019, Nature Communications.

[90]  A. Vlahou,et al.  Development and Validation of Multiple Reaction Monitoring (MRM) Assays for Clinical Applications. , 2019, Methods in molecular biology.

[91]  Sudhir Srivastava,et al.  A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[92]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[93]  C. Borchers,et al.  Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. , 2017, Analytical chemistry.

[94]  Blagoy Blagoev,et al.  UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites , 2018, Nature Structural & Molecular Biology.

[95]  Changxiao Liu,et al.  Direct comparison of LC-MS/MS and RIA methods for the pharmacokinetics assessment of human insulin in preclinical development. , 2018, Biomedical chromatography : BMC.

[96]  Oliver M. Bernhardt,et al.  Extending the Limits of Quantitative Proteome Profiling with Data-Independent Acquisition and Application to Acetaminophen-Treated Three-Dimensional Liver Microtissues* , 2015, Molecular & Cellular Proteomics.

[97]  Jeffrey W. Smith,et al.  Mass Spectrometry-Based Label-Free Quantitative Proteomics , 2009, Journal of biomedicine & biotechnology.

[98]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[99]  Youngsoo Kim,et al.  Method Validation by CPTAC Guidelines for Multi-protein Marker Assays Using Multiple Reaction Monitoring-mass Spectrometry , 2019, Biotechnology and Bioprocess Engineering.

[100]  Christoph H Borchers,et al.  Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry , 2018, Expert review of proteomics.

[101]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[102]  Ben Birkman,et al.  The Cystic Fibrosis Foundation , 2017 .

[103]  G. Jarvik,et al.  Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. , 2015, Journal of proteomics.

[104]  Yassene Mohammed,et al.  PeptidePicker: a scientific workflow with web interface for selecting appropriate peptides for targeted proteomics experiments. , 2014, Journal of proteomics.

[105]  R. Bast,et al.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. , 2013, Clinical chemistry.

[106]  D. Chan,et al.  The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[107]  J. Moul,et al.  Prostate specific antigen recurrence after definitive therapy. , 2007, The Journal of urology.

[108]  H. Woo,et al.  Current Status of Biomarkers for Prostate Cancer , 2013, International journal of molecular sciences.

[109]  Erin E. Chambers,et al.  Multidimensional LC-MS/MS enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma. , 2014, Analytical chemistry.

[110]  Albert Sickmann,et al.  Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. , 2012, Journal of proteomics.

[111]  Loïc Dayon,et al.  Obesity shows preserved plasma proteome in large independent clinical cohorts , 2018, Scientific Reports.

[112]  Juncong Yang,et al.  MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma , 2012, Proteomics.

[113]  Thomas Stoll,et al.  Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease , 2017, EuPA open proteomics.

[114]  Gary D Bader,et al.  The human genome and drug discovery after a decade. Roads (still) not taken , 2011, 1102.0448.

[115]  Scott R. Kronewitter,et al.  Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. , 2012, Journal of proteomics.

[116]  Ruedi Aebersold,et al.  Targeted proteomic strategy for clinical biomarker discovery , 2009, Molecular oncology.

[117]  Mehdi Mirzaei,et al.  Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment , 2015 .

[118]  Bernard F King,et al.  Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.

[119]  L. McDonnell,et al.  Set of Novel Automated Quantitative Microproteomics Protocols for Small Sample Amounts and Its Application to Kidney Tissue Substructures. , 2016, Journal of proteome research.

[120]  E. Lundberg,et al.  Antibody performance in western blot applications is context-dependent. , 2014, Biotechnology Journal.

[121]  Derek J. Bailey,et al.  Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.

[122]  Y. Kooyk,et al.  The tumour glyco-code as a novel immune checkpoint for immunotherapy , 2018, Nature Reviews Immunology.

[123]  C. Borchers,et al.  An MRM‐Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions , 2018, Proteomics. Clinical applications.

[124]  M. Panteghini,et al.  Standardisation of cardiac troponin I measurement: past and present , 2010, Pathology.

[125]  Matthias Mann,et al.  A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics* , 2018, Molecular & Cellular Proteomics.

[126]  J. Senior Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges , 2014, Drug Safety.

[127]  B. Domon,et al.  Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.

[128]  N. Anderson,et al.  Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences. , 2014, American journal of clinical pathology.

[129]  C. Borchers,et al.  Improving the biomarker pipeline. , 2010, Clinical chemistry.

[130]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[131]  C. Libioulle,et al.  3-years experience review of neonatal screening for hemoglobin disorders using tandem mass spectrometry. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[132]  P. Lescuyer,et al.  Identification of hemoglobin variants by top-down mass spectrometry using selected diagnostic product ions , 2015, Analytical and Bioanalytical Chemistry.

[133]  Jan L.A. Voskuil,et al.  The challenges with the validation of research antibodies , 2017, F1000Research.

[134]  Richard D. Smith Mass spectrometry in biomarker applications: from untargeted discovery to targeted verification, and implications for platform convergence and clinical application. , 2012, Clinical chemistry.

[135]  Yassene Mohammed,et al.  A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma. , 2015, Bioanalysis.

[136]  Wilhelm Schänzer,et al.  Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. , 2012, Methods.

[137]  Thomas Laurell,et al.  Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. , 2010, Journal of proteomics.